Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court

The pharmaceutical industry is aiming to strike down Medicare’s historic new powers to slash drug prices for seniors through a Supreme Court ruling, legal experts say.

Drugmaker Merck, the U.S. Chamber of Commerce and Bristol Myers Squibb filed separate lawsuits within days of each other this month asking federal courts in Washington, D.C., the Southern District of Ohio, and New Jersey to declare the price negotiations unconstitutional under the First and Fifth amendments.

The lawsuits are the opening salvo in what will go down as a historic and potentially decisive battle over the federal government’s efforts to control rising drug prices.

The Inflation Reduction Act, passed in a narrow party-line vote last year, gave Medicare the power to negotiate prices for the first time in the program’s nearly 60-year history — a watershed moment that the Democratic Party had long fought for.

The pharmaceutical industry views the program as posing a major threat to revenue growth and profits. The companies claim the program will stifle future drug development in the U.S.

Merck fears its blockbuster cancer therapy Keytruda, which generated 35% of the company’s $59 billion in revenue for 2022, will be targeted by the program in the future. The company also worries the federal government will select its Type 2 diabetes drug Januvia, which generated $2.8 billion in revenue in 2022, for negotiations this year.

Drugmaker Abbvie, a member of the Chamber of Commerce’s Dayton, Ohio, chapter, is defending its blood cancer drug Imbruvica, which generated $4.6 billion in revenue last year, or about 8% of its total sales.

And Bristol Myers Squibb is trying protect its blood thinner Eliquis, which brought in $11.8 billion in sales last year, or about 25% of the company’s $46 billion total revenue for 2022.

These are the first lawsuits challenging Medicare’s new powers, but they are unlikely to be the last.

The big drugmakers’ lobby group, the Pharmaceutical Research and Manufacturers of America, told CNBC in a statement that it supports the claims made in the lawsuits.

A spokesperson for PhRMA said the organization is also considering litigation against Medicare. PhRMA’s members include other big drugmakers like Eli Lilly, Pfizer and Johnson & Johnson.

Legal experts and financial analysts who cover the pharmaceutical industry said Merck, the chamber and Bristol Myers Squibb will try to litigate their claims all the way to the high court.

“These lawsuits were written with the Supreme Court in mind,” said Robin Feldman, an expert on intellectual property and health law at the University of California College of the Law in San Francisco.

Nicholas Bagley, a former Justice Department attorney, said the high court is the “big fish.” Any decision striking down the Medicare price negotiations would ultimately have to be made by the justices, said Bagley, former chief legal counsel to Michigan Gov. Gretchen Whitmer.

Chris Meekins, an analyst with Raymond James, noted that the all four attorneys representing Merck previously served as clerks to conservative Supreme Court justices: They clerked for Antonin Scalia, Brett Kavanaugh and Neil Gorsuch.

“That is noteworthy in that it is clear to us that Merck is ready and willing to take this all the way to the Supreme Court if needed,” Meekins wrote in analyst note.

Merck, the chamber and Bristol Myers Squibb filed their lawsuits ahead of two key deadlines.

Health and Human Services Secretary Xavier Becerra will publish a list by Sept. 1 of the 10 drugs that Medicare has selected for the negotiations. The drugmakers then have to agree to participate and file manufacturing data to the Centers for Medicare and Medicaid Services the following month.

The list of drugs subject to negotiation could include Pfizer‘s Ibrance, Johnson & Johnson‘s Xarelto, Eli Lilly‘s Jardiance, Amgen‘s Enbrel and AstraZeneca‘s Symbicort, among others, according to a March analysis published in the Journal of Managed Care and Specialty Pharmacy.

Pfizer CEO Albert Bourla told Reuters in May that he expects legal action to be taken against Medicare over the negotiations, though he said it is unclear if the drugmakers will be able to stop the law’s implementation before the 2026 cuts go into effect.

Eli Lilly, in a statement to CNBC, said the company shares the companies’ concerns and will evaluate the negotiations implementation to “determine any possible actions.”

Bagby also believes the issue is heading for the Supreme Court. She said the companies will probably scatter their cases around the country — like Merck, the chamber and Bristol Myers Squibb did — in an attempt to get federal appellate courts to issue competing decisions.

The Merck case in Washington, D.C., district court would move on appeal to the D.C. Circuit Court of Appeals, which has a majority of judges appointed by Democratic presidents.

The chamber’s case would be appealed to the U.S. Sixth Circuit Court of Appeals, which has a majority of judges appointed by Republican presidents, particularly Donald Trump.

And Bristol Myers Squibb’s case would head to the U.S. Third Circuit Court of Appeals, which also has a slight majority of judges appointed by Republicans.

If circuit court decisions on the matter contradict one another, the Supreme Court would step in to decide the issue, Bagby said.

White House press secretary Karine Jean-Pierre said the Biden administration is confident it will succeed in the courts.

“There is nothing in the Constitution that prevents Medicare from negotiating lower drug prices,” Jean-Pierre said in a statement.

And Beccera added that “we’ll vigorously defend the President’s drug price negotiation law, which is already lowering health care costs for seniors and people with disabilities.”

“The law is on our side,” Becerra said in a statement.